Patients enrolled in protocol, with clinical outcome
| Patient ID | Gender | Group | Stage | No. of vaccines | Reason off protocol | Time to progression (yr) | Site of progression | Follow-upa (yr) | At last follow-up | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alive? | NED? | ||||||||||
| 1101 | M | 1 | III | 4 | Progression | 0.5 | Multidistant | 0.6 | N | N | |
| 1102 | M | 1 | III | 7 | 4.6 | Y | Y | ||||
| 1103 | F | 2 | IIB | 7 | 4.5 | Y | Y | ||||
| 1104 | F | 2 | IV | 7 | 1.7 | Skin | 4.6 | Y | Y | ||
| 1105 | F | 1 | IIB | 7 | 2.5 | Nodes | 4.4 | Y | Y | ||
| 1106 | F | 2 | III | 7 | 4.1 | Y | Y | ||||
| 1107 | M | 1 | III | 2 | Progression | 0.2 | Intransit | 1.6 | N | N | |
| 1108 | M | 2 | III | 7 | 3.6 | Y | Y | ||||
| 1109 | M | 2 | IIIb | 2 | Progression | 0.2 | Lung | 0.4 | N | N | |
| 1110 | M | 3 | III | 7 | 1.8 | Nodes | 3.0 | Y | Y | ||
| 1111 | F | 3 | III | 6 | Other cancer | 0.9 | Y | Y | |||
| 1112 | M | 6 | III | 7 | 3.1 | Y | Y | ||||
| 1113 | M | 5 | III | 6 | Noncompliance | 2.6 | Y | Y | |||
| 1114 | M | 4 | IV | 4 | Progression | 0.4 | Nodes | 1.2 | N | N | |
| 1115 | M | 6 | III | 4 | Progr or MIc | 0.5 | Not evaluable | 0.5 | N | N | |
| 1116 | F | 6 | III | 3 | Progression | 0.3 | Intransit | 0.9 | Y | N | |
| 1117 | M | 3 | III | 7 | 2.4 | Y | Y | ||||
| 1118 | M | 5 | IV | 7 | 2.1 | Y | Y | ||||
| 1119 | F | 5 | IV | 7 | 1.5 | Liver | 1.9 | Y | Y | ||
| 1120 | F | 4 | IIB | 7 | 1.6 | Y | Y | ||||
| 1121 | F | 5 | III | 4 | Progression | 0.5 | Intransit | 1.4 | Y | N | |
| 1122 | F | 3 | III | 6 | Adverse event | 1.5 | Y | Y | |||
a Mean follow-up, 2.3 years; median follow-up, 2.0 years; median follow-up of living patients, 2.6 years. NED, no evidence of disease.
b This patient had minimal measurable disease at protocol entry.
c Progr or MI, progression or myocardial infarction.